PharmaShots | Incisive News in 3 Shots

Subscribe Now

Lucentis

Lupin Reports the P-III Study Completion of LUBT010 (Biosimilar, Lucentis) for Neovascular Age-related Macular Degeneration

Lupin Reports the P-III Study Completion of LUBT010 (Biosimilar, Lucentis) for Neovascular Age-related Macular Degeneration

August 5, 2024

Enzene Biosciences Reports the Launch of Ranibizumab Biosimilar for the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

Enzene Biosciences Reports the Launch of Ranibizumab Biosimilar for the Treatment of Neovascular Age-Related Macular Degeneration...

December 4, 2023

Xbrane Reports the US FDA Acceptance of BLA for Lucentis Biosimilar to Treat Serious Eye Diseases

Xbrane Reports the US FDA Acceptance of BLA for Lucentis Biosimilar to Treat Serious Eye Diseases

June 21, 2023

Xbrane Resubmit the BLA for Ranibizumab Biosimilar to Treat Serious Eye Disease

Xbrane Resubmit the BLA for Ranibizumab Biosimilar to Treat Serious Eye Disease

July 4, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us